Positive new phase III data showing Adherex Technologies Inc.'s sodium thiosulfate (STS) reduced hearing loss in children with cancer on cisplatin chemotherapy moved the company a step closer to filing a new drug application for the orphan drug next year. If approved it would become the first such therapy available in the U.S.